We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

MALDI-TOF Can Predict Antimicrobial Resistance in Clinical Samples

By LabMedica International staff writers
Posted on 27 Jan 2022
Print article
Image: The Microflex Biotyper MALDI-TOF Mass Spectrometry System for fast, accurate and cost-effective microbial identification (Photo courtesy of Bruker Daltonics)
Image: The Microflex Biotyper MALDI-TOF Mass Spectrometry System for fast, accurate and cost-effective microbial identification (Photo courtesy of Bruker Daltonics)
Antimicrobial-resistant bacteria and fungi pose a serious and increasing threat to the achievements of modern medicine. Infections with antimicrobial-resistant pathogens are associated with substantial morbidity, mortality and healthcare costs.

Matrix-assisted laser desorption/ionization–time of flight (MALDI-TOF) mass spectrometry enables rapid microbial species identification. In only a few minutes, MALDI-TOF mass spectrometry can be used to characterize the protein composition of single bacterial or fungal colonies, and the results are available usually within 24 hours after sample collection.

Medical Microbiologists at the University of Basel (Basel, Switzerland) and their colleagues developed a database, which they dubbed the Database of Resistance Information on Antimicrobials and MALDI-TOF Mass Spectra, or DRIAMS, by collecting MALDI-TOF mass spectra and resistance information on more than 30,000 clinical isolates from four different Swiss clinical labs.

The largest collection within DRIAMS, called DRIAMS-A, came from University Hospital Basel (Basel, Switzerland) and included 145,341 mass spectra. Most of the spectra could be generated from clinical samples within 24 hours. All laboratories used the Microflex Biotyper System (Bruker Daltonics, Bremen, Germany), which is a widely used MALDI-TOF mass spectrometry system. Resistance categories for bacteria were determined using either microdilution assays (VITEK 2, BioMérieux, Marcy l'Etoile France), minimum inhibitory concentration (MIC) stripe tests (Liofilchem, Roseto degli Abruzzi, Italy) or disc diffusion tests (Thermo Fisher Scientific, Waltham MA, USA). Resistance categories for yeast were determined using Thermo Fisher Scientific’s Sensititre Yeast One.

The investigators particular focused their analyses on three key clinical pathogens, Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae, and antibiotics used to treat infections they cause. For all three, they reported a high overall performance. The classifier could predict S. aureus resistance to oxacillin with 80% accuracy as well as E. coli and K. pneumoniae resistance to ceftriaxone currently with 74% accuracy for both. For 31 of the 42 antibiotics studied, the classifier generated could correctly classify resistance with 80% accuracy. In a retrospective clinical case study, the researchers reviewed 416 cases with positive S. aureus, E. coli, and K. pneumoniae cultures. For 63 of these, an infectious disease specialist was consulted to help guide antibiotic treatment.

The authors concluded that their retrospective clinical case study shows that their classifier might have a beneficial impact on patient treatment and promote antibiotic stewardship. MALDI-TOF mass spectra-based machine learning may thus be an important new tool for treatment optimization. The study was published on January 10, 2022 in the journal Nature Medicine.

Related Links:
University of Basel
University Hospital Basel
Bruker Daltonics
BioMérieux
Liofilchem
Thermo Fisher Scientific


Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
New
Washer Dispenser
EL406
New
Molecular Diagnostic System
FlashDetect Flash48
New
3-DIFF Hematology Analyzer
MYTHIC 18

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.